Article 1: https://www.nytimes.com/2023/03/01/science/dna-hunter-gatherers-europe.html 

The article Ancient DNA Reveals History of Hunter-Gatherers in Europe by reporter Carl Zimmer was published on March 1st, 2023. This article discusses the results of recent genetic studies done on newly discovered archaeological remains. It is a well-established fact that the earliest modern humans emerged in Africa approximately 60 thousand years ago (paragraph 10). At some point after their emergence in Africa, different groups separated, and modern humans reached Europe. This can be traced back to 45 thousand years ago (paragraph 12). The new discovery suggests that 2 specific groups of humans, the Fournol and Vestonice, migrated into Europe in different waves, yet “lived for several thousand years sharing the Gravettian culture but remaining genetically distinct” (paragraph 21). This news is seen as “groundbreaking” by scientists in the archaeological world and could lead to new discoveries on the cultural contacts between the two. The interactions between humans and their natural environment also influenced migration patterns. The ice age separated groups of humans into further distinctions, and altogether the scientists believe this new genetic discovery could have revealed up to 8 different populations of early Europeans.  

Article 2: https://www.nytimes.com/2023/03/04/health/tricuspid-valve-clip-leakage.html 

The article New Treatment Could Help Fix the Heart’s ‘Forgotten Valve’ by reporter Gina Kolata was published on March 4th, 2023. This article discusses a newly tested procedure that addresses heart complications in a conservative and less-risky approach. “More than 1 million mostly older Americans have seriously leaking tricuspids” (paragraph 2) and face symptoms such as “fatigue, abdominal distention, swollen legs and general feelings of malaise” (paragraph 3), usually ending in heart failure. Previously, there have been no reliable techniques to mitigate the side effects of the leaky tricuspid valve. A recent clinical trial done by the medical device company, Abbott, reports high success rates in “treatment that involves clipping the floppy tricuspid valve to make it smaller and better able to function” (paragraph 6). Abbott researchers report that many patients who were treated with the clip have been able to return to their lives with minimal symptoms (paragraph 8). Although it has only been one year since this trial and long-term effects are still unknown, the treatment has less than a one-percent mortality risk and is seen as a “huge win” in the eyes of many cardiologists (paragraphs 9-11).